Literature DB >> 22412122

Is it possible to identify clinically useful prognostic groups for patients with desmoid tumors?

Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Eisuke Arai, Naoki Ishiguro.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22412122     DOI： 10.1200/JCO.2011.39.8636

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.

Authors:  Shunsuke Hamada; Hiroshi Urakawa; Eiji Kozawa; Naohisa Futamura; Kunihiro Ikuta; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Tumour Biol       Date:  2014-01-05

2.  Simple resection of truncal desmoid tumors: A case series.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Shunsuke Hamada; Eiji Kozawa; Kunihiro Ikuta; Naoki Ishiguro
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

3.  CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.

Authors:  Shunsuke Hamada; Naohisa Futamura; Kunihiro Ikuta; Hiroshi Urakawa; Eiji Kozawa; Naoki Ishiguro; Yoshihiro Nishida
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

4.  Characteristics of cultured desmoid cells with different CTNNB1 mutation status.

Authors:  Shunsuke Hamada; Hiroshi Urakawa; Eiji Kozawa; Eisuke Arai; Kunihiro Ikuta; Tomohisa Sakai; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Cancer Med       Date:  2015-12-21       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.